Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | OT |
HCP stated female patient started her series at age 45 and has not received their 3rd dose within the guidelines of PI.; No additional AE reported; This spontaneous report was received from a Pharmacist and refers to a 45-year-old female patient. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medication. On an unknown date in November 2024, the patient was vaccinated with the first dose of with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported). On an unknown date in December 2024, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported). The reporter stated that the patient did not receive the third dose. No additional adverse events were reported. Additional information is not expected.